Tech Company Financing Transactions
ApoGen Biotechnologies Funding Round
ApoGen Biotechnologies, based in Seattle, raised $7 million from AbbVie Biotech Ventures, Alexandria Venture Investments and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
12/13/2016
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Investors
Proceeds Purpose
We are excited to invest Accelerator's unique startup resources to potentially develop these promising technologies for cancer patients in need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2815 Eastlake Ave. East 300
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Website
Email Address
Overview
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Santini
Founder
Daniel Harki
Founder
Reuben Harris
Browse more venture capital transactions:
Prev: 12/13/2016: Dynamic Signal venture capital transaction
Next: 12/13/2016: eGifter venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs